written notice of intent to submit such an adverse comment, were received within the comment period, the regulation would become effective on April 23, 1998. No adverse comments were received, and thus this document confirms that this direct final rule will become effective on that date.

Correction

In rule FR Doc. 97–28750 published in the **Federal Register** on October 30, 1997, 62 FR 58644, make the following correction to the Keokuk, IA, Class E airspace designation incorporated by reference in 14 CFR 71.1:

§ 71.1 [Corrected]

On page 58645, in the third column, in the airspace designation, line 5, correct ''(Lat. 40°27′45″N., long. 91°26′01″ W.)'' to read ''(Lat. 40°27′53″ N., long. 91°26′01″ W.)''.

Issued in Kansas City, MO on January 27, 1998.

Christopher R. Blum,

Acting Manager, Air Traffic Division, Central Region.

[FR Doc. 98–3961 Filed 2–18–98; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Airspace Docket No. 97–ACE–22]

Amendment to Class E Airspace; St. Louis, MO; Correction

AGENCY: Federal Aviation Administration, DOT.

ACTION: Direct final rule; confirmation of effective date and correction.

SUMMARY: This document confirms the effective date of a direct final rule which revises Class E airspace at St. Louis, MO, and corrects an error in the airspace designation as published in the direct final rule.

DATES: The direct final rule published at 62 FR 64148 is effective on 0901 UTC April 23, 1998.

The correction is effective on 0901 UTC April 23, 1998.

FOR FURTHER INFORMATION CONTACT: Kathy Randolph, Air Traffic Division, Airspace Branch, ACE–520C, Federal Aviation Administration, 601 East 12th Street, Kansas City, Missouri 64106; telephone: (816) 426–3408.

SUPPLEMENTARY INFORMATION: On December 4, 1997, the FAA published in the **Federal Register** a direct final rule and request for comments which modified the Class E airspace at St. Louis, MO (FR Document 97–31704, 62 FR 64148, Airspace Docket No. 97–ACE–22). An error was subsequently discovered in the Class E airspace designation. This action corrects that error and confirms the effective date of the direct final rule.

The FAA uses the direct final rulemaking procedure for a non-controversial rule where the FAA believes that there will be no adverse public comment. This direct final rule advised the public that no adverse comments were anticipated, and that unless a written adverse comment, or a written notice of intent to submit such an adverse comment, were received within the comment period, the regulation would become effective on April 23, 1998. No adverse comments were received, and thus this document confirms that this direct final rule will become effective on that date.

Correction

In rule FR Doc. 97–31704 published in the **Federal Register** on December 4, 1997, 62 FR 64148, make the following correction to the St. Louis, MO, Class E airspace designation incorporated by reference in 14 CFR 71.1:

§ 71.1 [Corrected]

On page 64149, in the third column, in the airspace designation, line 5, correct ''(Lat. 38°39′43″N., long. 90°39′00″W.)'' to read ''(Lat. 38°39′43″N., long. 90°39′04″W.)''.

Issued in Kansas City, MO on January 27, 1998.

Christopher R. Blum,

Acting Manager, Air Traffic Division, Central Region.

[FR Doc. 98–3960 Filed 2–18–98; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 520

New Animal Drugs; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for a new animal drug application (NADA) from PM Resources, Inc., to Akzo Nobel Surface Chemistry AB.

EFFECTIVE DATE: February 19, 1998

FOR FURTHER INFORMATION CONTACT: Thomas J. McKay, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0213.

SUPPLEMENTARY INFORMATION: PM Resources, Inc., 13001 St. Charles Rock Rd., Bridgeton, MO 63044, has informed FDA that it has transferred ownership of, and all rights and interests in approved NADA 10–886 (Piperazine Monohydrochloride liquid) to Akzo Nobel Surface Chemistry AB, Box 851, S–44485 Stenungsund, Sweden. Accordingly, the agency is amending the regulations in 21 CFR 520.1806 to reflect the change of sponsor. The agency is also amending the regulations in 21 CFR 510.600(c)(1) and (c)(2) by alphabetically adding a new listing for Akzo Nobel Surface Chemistry AB.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR Parts 510 and 520 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding a new entry for ''Akzo Nobel Surface Chemistry AB'' and in the table in paragraph (c)(2) by numerically adding a new entry for ''063765'' to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

* * * * *

(c) * * *

(1) * * *

Firm name and address	Drug labeler code
* * *	* * * *
Akzo Nobel Surface Chemistry AB, Box 851, S–44485 Stenungsund, Sweden	063765
* * *	* * * *

(2) * * *

Drug labeler code	Firm name and address
* * *	* * * *
063765	Akzo Nobel Surface Chemistry AB, Box 851, S–44485 Stenungsund, Sweden.
* * *	* * * *

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 520.1806 [Amended]

4. Section 520.1806 *Piperazine monohydrochloride liquid* is amended in paragraph (b) by removing ''See 017135 and 060594'' and adding in its place ''See Nos. 017135 and 063765''.

Dated: January 21, 1998.

Andrew J. Beaulieau,

Deputy Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 98–4076 Filed 2–18–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 522

Animal Drugs, Feeds, and Related Products; Doxycycline Hyclate

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Heska Corp. The NADA provides for use of doxycycline hyclate solution for treatment and control of periodontal disease in dogs by application subgingivally to the periodontal pocket(s) of affected teeth.

EFFECTIVE DATE: February 19, 1998.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV–110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20857, 301–594–1612.

SUPPLEMENTARY INFORMATION: Heska Corp., 1825 Sharp Point Dr., Fort Collins, CO 80525, filed NADA 141–082, which provides for use of doxycycline hyclate solution for treatment and control of periodontal disease in dogs by application subgingivally to the periodontal pocket(s) of affected teeth. The NADA is approved as of November 19, 1997, and the regulations are amended by adding new 21 CFR 522.778 to reflect the approval. The basis for approval is discussed in the freedom of information summary.

Also, the regulations are amended in § 510.600(c) to add the new sponsor to the list of sponsors of approved applications.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(i)), this approval qualifies for 5 years of marketing exclusivity beginning November 19, 1997, because no active ingredient, including any ester or salt of the active ingredient, has been previously approved in any other application filed under section 512(b)(1) of the act.

FDA has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects in

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Part 522

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

2. Section 510.600 is amended in paragraph (c)(1) by alphabetically adding a new entry for ''Heska Corp.'' and in paragraph (c)(2) by numerically